Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02952534




Registration number
NCT02952534
Ethics application status
Date submitted
24/10/2016
Date registered
2/11/2016
Date last updated
9/06/2023

Titles & IDs
Public title
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Scientific title
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Secondary ID [1] 0 0
2016-003162-13
Secondary ID [2] 0 0
CO-338-052
Universal Trial Number (UTN)
Trial acronym
TRITON2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Castration Resistant Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rucaparib

Experimental: Rucaparib - Oral rucaparib (monotherapy)


Treatment: Drugs: Rucaparib
Rucaparib will be administered daily
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)
Timepoint [1] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [1] 0 0
Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Investigator (INV)
Timepoint [1] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [2] 0 0
Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Central Independent Radiology Review (IRR)
Timepoint [2] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [3] 0 0
Duration of Response (DOR) by Gene in Patients With Confirmed Response Per Investigator
Timepoint [3] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [4] 0 0
Confirmed PSA Response (= 50% Decrease) by Gene as Assessed by Local Laboratory
Timepoint [4] 0 0
PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.
Secondary outcome [5] 0 0
Confirmed PSA Response (= 90% Decrease) by Gene as Assessed by Local Laboratory
Timepoint [5] 0 0
PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.
Secondary outcome [6] 0 0
Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Central Independent Radiology Review (IRR)
Timepoint [6] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [7] 0 0
Radiologic Progression-free Survival (rPFS) by Gene in All Patients Per Investigator
Timepoint [7] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [8] 0 0
Overall Survival (OS) by Gene
Timepoint [8] 0 0
From date of first dose until event, loss to follow-up, withdrawal of consent, or study closure: an overall median of approximately 33.1 months
Secondary outcome [9] 0 0
Clinical Benefit Rate (CBR) by Gene Per Central Independent Radiology Review (IRR)
Timepoint [9] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [10] 0 0
Clinical Benefit Rate (CBR) by Gene Per Investigator
Timepoint [10] 0 0
Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years.
Secondary outcome [11] 0 0
Time to PSA Progression by Gene
Timepoint [11] 0 0
PSA assessments were done at baseline, Week 5, Week 9, every 4 weeks thereafter, and at Treatment Discontinuation. Total follow-up was up to approximately 39 months.
Secondary outcome [12] 0 0
Steady State Trough (Cmin) Level Rucaparib Concentrations
Timepoint [12] 0 0
Participants were assessed at Study Day 29, Day 57, Day 85 and Day 113

Eligibility
Key inclusion criteria
* Be 18 years old at the time the informed consent form is signed
* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
* Be surgically or medically castrated, with serum testosterone levels of = 50 ng/dL (1.73 nM)
* Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease
* Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
* Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy
* Symptomatic and/or untreated central nervous system metastases
* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
27/07/2021
Sample size
Target
Accrual to date
Final
277
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC
Recruitment hospital [1] 0 0
Northern Cancer Insitute, St. Leonards - Saint Leonards
Recruitment hospital [2] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [3] 0 0
Peninsula & Southeast Oncology - Frankston
Recruitment hospital [4] 0 0
Barwon Health, University Hospital Geelong - Geelong
Recruitment hospital [5] 0 0
Cabrini Hospital - Malvern
Recruitment hospital [6] 0 0
Southside Cancer Care Centre - Miranda
Recruitment hospital [7] 0 0
Orange Health Services - Orange
Recruitment hospital [8] 0 0
St John of God Hospital, Subiaco - Subiaco
Recruitment hospital [9] 0 0
Riverina Cancer Care Centre - Wagga Wagga
Recruitment postcode(s) [1] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment postcode(s) [5] 0 0
3144 - Malvern
Recruitment postcode(s) [6] 0 0
2228 - Miranda
Recruitment postcode(s) [7] 0 0
2800 - Orange
Recruitment postcode(s) [8] 0 0
6008 - Subiaco
Recruitment postcode(s) [9] 0 0
2650 - Wagga Wagga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oregon
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Belgium
State/province [29] 0 0
Antwerp
Country [30] 0 0
Belgium
State/province [30] 0 0
Gent
Country [31] 0 0
Belgium
State/province [31] 0 0
Kortrijk
Country [32] 0 0
Belgium
State/province [32] 0 0
Liège
Country [33] 0 0
Belgium
State/province [33] 0 0
Roeselare
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Toronto
Country [36] 0 0
Denmark
State/province [36] 0 0
Copenhagen
Country [37] 0 0
Denmark
State/province [37] 0 0
Herlev
Country [38] 0 0
Denmark
State/province [38] 0 0
Vejle
Country [39] 0 0
France
State/province [39] 0 0
Caen
Country [40] 0 0
France
State/province [40] 0 0
Dijon
Country [41] 0 0
France
State/province [41] 0 0
Le Mans
Country [42] 0 0
France
State/province [42] 0 0
Lille
Country [43] 0 0
France
State/province [43] 0 0
Nancy
Country [44] 0 0
France
State/province [44] 0 0
Paris
Country [45] 0 0
France
State/province [45] 0 0
Plérin
Country [46] 0 0
France
State/province [46] 0 0
Rennes
Country [47] 0 0
Germany
State/province [47] 0 0
Augsburg
Country [48] 0 0
Germany
State/province [48] 0 0
Berlin
Country [49] 0 0
Germany
State/province [49] 0 0
Dresden
Country [50] 0 0
Germany
State/province [50] 0 0
Dusseldorf
Country [51] 0 0
Germany
State/province [51] 0 0
Emmendingen
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Heidelberg
Country [54] 0 0
Germany
State/province [54] 0 0
Jena
Country [55] 0 0
Germany
State/province [55] 0 0
Köln
Country [56] 0 0
Germany
State/province [56] 0 0
Lübeck
Country [57] 0 0
Germany
State/province [57] 0 0
Mannheim
Country [58] 0 0
Germany
State/province [58] 0 0
Nürtingen
Country [59] 0 0
Germany
State/province [59] 0 0
Tuebingen
Country [60] 0 0
Germany
State/province [60] 0 0
Wuppertal
Country [61] 0 0
Ireland
State/province [61] 0 0
Cork
Country [62] 0 0
Ireland
State/province [62] 0 0
Dublin
Country [63] 0 0
Israel
State/province [63] 0 0
Haifa
Country [64] 0 0
Israel
State/province [64] 0 0
Jerusalem
Country [65] 0 0
Israel
State/province [65] 0 0
Kfar Saba
Country [66] 0 0
Israel
State/province [66] 0 0
Petach Tikva
Country [67] 0 0
Israel
State/province [67] 0 0
Ramat Gan
Country [68] 0 0
Israel
State/province [68] 0 0
Tel Aviv
Country [69] 0 0
Italy
State/province [69] 0 0
Arezzo
Country [70] 0 0
Italy
State/province [70] 0 0
Faenza
Country [71] 0 0
Italy
State/province [71] 0 0
Milano
Country [72] 0 0
Italy
State/province [72] 0 0
Modena
Country [73] 0 0
Italy
State/province [73] 0 0
Rome
Country [74] 0 0
Italy
State/province [74] 0 0
Terni
Country [75] 0 0
Italy
State/province [75] 0 0
Trento
Country [76] 0 0
Spain
State/province [76] 0 0
Badalona
Country [77] 0 0
Spain
State/province [77] 0 0
Barcelona
Country [78] 0 0
Spain
State/province [78] 0 0
Guadalajara
Country [79] 0 0
Spain
State/province [79] 0 0
Lugo
Country [80] 0 0
Spain
State/province [80] 0 0
Madrid
Country [81] 0 0
Spain
State/province [81] 0 0
Oviedo
Country [82] 0 0
Spain
State/province [82] 0 0
Sabadell
Country [83] 0 0
Spain
State/province [83] 0 0
Santander
Country [84] 0 0
Spain
State/province [84] 0 0
Sevilla
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Berkshire
Country [87] 0 0
United Kingdom
State/province [87] 0 0
England
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Surrey
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Headington
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Liverpool
Country [91] 0 0
United Kingdom
State/province [91] 0 0
London
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Southampton
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Taunton
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
pharmaand GmbH
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Foundation Medicine
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
Trial website
https://clinicaltrials.gov/study/NCT02952534
Trial related presentations / publications
Green ML, Ma SC, Goble S, Giordano H, Maloney L, Simmons AD, Beltman J, Harding TC, Xiao JJ. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer Chemother Pharmacol. 2022 May;89(5):671-682. doi: 10.1007/s00280-022-04413-7. Epub 2022 Apr 10.
Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02952534